ENDRA Life Sciences (NDRA) director awarded 60,324 RSUs at $0

Rhea-AI Filing Summary

ENDRA Life Sciences director Michael Harsh reported an equity award of 60,324 shares on January 21, 2026. The filing shows these are restricted stock units (RSUs) that convert into common stock on a one-for-one basis and will vest in full on January 21, 2026. The transaction was recorded at a price of $0 per share, indicating a compensatory grant rather than an open-market purchase. Following this award, Harsh beneficially owned 65,710 shares of common stock, and his holdings include unvested RSUs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harsh Michael

(Last) (First) (Middle)

C/O ENDRA LIFE SCIENCES INC.

3600 GREEN COURT, SUITE 350

(Street)

ANN ARBOR MI 48105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ENDRA Life Sciences Inc. [ NDRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	01/21/2026		A		60,324(2)	A	$0	65,710	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Holdings include unvested restricted stock units ("RSUs").

2. Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on January 21, 2026.

	/s/ Michael Harsh by Mark Busch, attorney-in-fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NDRA director Michael Harsh report?

Director Michael Harsh reported the acquisition of 60,324 shares of ENDRA Life Sciences common stock on January 21, 2026, recorded as an equity award at $0 per share.

Are the 60,324 NDRA shares acquired by Michael Harsh restricted stock units (RSUs)?

Yes. A footnote explains the 60,324 shares represent restricted stock units (RSUs) that convert into common stock on a one-for-one basis.

When do Michael Harsh’s NDRA RSUs vest?

The filing states that these RSUs will vest in full on January 21, 2026, at which time they convert into ENDRA Life Sciences common stock on a one-for-one basis.

How many NDRA shares does Michael Harsh own after this Form 4 transaction?

After the reported RSU award, Michael Harsh beneficially owned 65,710 shares of ENDRA Life Sciences common stock, including unvested RSUs.

Was there any cash paid for the NDRA shares reported by Michael Harsh?

No. The Form 4 lists a transaction price of $0 per share for the 60,324 shares, indicating they were received as part of an equity compensation award, not bought on the open market.

Is Michael Harsh a director or officer of ENDRA Life Sciences (NDRA)?

The Form 4 identifies Michael Harsh as a director of ENDRA Life Sciences Inc. and not as an officer or 10% owner.